Adial Pharmaceuticals

Adial Pharmaceuticals is a Charlottesville, Virginia-based clinical-stage biopharmaceutical company focused on developing treatments for alcohol use disorder and other addictions. Its lead therapeutic candidate targets the serotonin-3 receptor to reduce alcohol consumption. The company is publicly traded on the Nasdaq under the ticker ADIL.